Association of HBsAg Positivity and HBV Reactivation in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR-TKIs: A Retrospective Cohort Study
- 1Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
- 2State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, Sichuan University, Chengdu 610041, China
- 3Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China
Abstract
Background: EGFR-TKIs serve as standard first-line targeted therapy for EGFR-mutant lung adenocarcinoma (LUAD). Real-world data on the prognostic role of baseline HBsAg positivity and the risk of HBV reactivation during EGFR-TKI treatment remain limited, particularly in HBV-endemic Chinese populations. Methods: This retrospective single-center cohort study enrolled 580 consecutive patients with stage III–IV EGFR-mutant LUAD who received EGFR-TKIs between 2013 and 2026. Patients were grouped by baseline HBsAg status; Kaplan–Meier curves and multivariable Cox models adjusted for key clinical covariates were used to evaluate progression-free survival (PFS) and overall survival (OS). HBV reactivation was defined by EASL criteria, with virological evaluation available for 51 of 82 HBsAg-positive patients. Results: Among all enrolled patients, 14.1% were HBsAg-positive. The HBV reactivation rate was 9.8% among evaluable HBsAg-positive patients, and reactivation was not independently linked to survival. After adjustment, baseline HBsAg positivity showed a borderline trend toward poorer OS (HR = 1.42, 95% CI, 0.99–2.04, p = 0.054) without significant PFS association (HR = 1.14, 95% CI, 0.80–1.62, p = 0.481). Liver metastasis independently predicted worse OS in HBsAg-positive patients (HR = 3.84, 95% CI, 1.65–8.94, p = 0.002). Conclusions: HBV reactivation was uncommon but warrants close monitoring during EGFR-TKI therapy. Baseline HBsAg positivity demonstrated only a non-significant trend toward inferior OS without affecting PFS. Routine HBsAg screening at diagnosis may facilitate risk stratification, and HBsAg-positive patients with liver metastasis require intensified surveillance.
Related
- Evaluation of clinical outcomes and prognostic factors in patients with metastatic appendiceal adenocarcinoma treated with first-line chemotherapy: A multi-institutional retrospective study
- Nonlinear association between baseline albumin-to-alkaline phosphatase ratio and overall survival in advanced NSCLC treated with anlotinib: a two-center retrospective cohort study
- Association of ABO and Rh blood groups with clinicopathological features and lymph node involvement in surgically treated thyroid malignancies: a retrospective single-center study.
- Association of nutritional-immune indicators and their dynamic changes with disease severity and wound healing in diabetic foot ulcers treated by tibial transverse transport: a retrospective study.
- Incremental Prognostic Information Beyond Nodal Positivity: The AJCC 8th Edition N1/N2 Subdivision and the Lymph Node Ratio in Resected Periampullary Adenocarcinoma
BibTeX
@article{sun2026association,
title = {{Association of HBsAg Positivity and HBV Reactivation in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR-TKIs: A Retrospective Cohort Study}},
author = {Jiayi Sun and Jingwen Lin and Honglin Li and Weimin Li and Panwen Tian and Yalun Li},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203373},
url = {https://www.mdpi.com/2072-6694/18/20/3373},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association of HBsAg Positivity and HBV Reactivation in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR-TKIs: A Retrospective Cohort Study
AU - Jiayi Sun
AU - Jingwen Lin
AU - Honglin Li
AU - Weimin Li
AU - Panwen Tian
AU - Yalun Li
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203373
UR - https://www.mdpi.com/2072-6694/18/20/3373
AB - Background: EGFR-TKIs serve as standard first-line targeted therapy for EGFR-mutant lung adenocarcinoma (LUAD). Real-world data on the prognostic role of baseline HBsAg positivity and the risk of HBV reactivation during EGFR-TKI treatment remain limited, particularly in HBV-endemic Chinese populations. Methods: This retrospective single-center cohort study enrolled 580 consecutive patients with stage III–IV EGFR-mutant LUAD who received EGFR-TKIs between 2013 and 2026. Patients were grouped by baseline HBsAg status; Kaplan–Meier curves and multivariable Cox models adjusted for key clinical covariates were used to evaluate progression-free survival (PFS) and overall survival (OS). HBV reactivation was defined by EASL criteria, with virological evaluation available for 51 of 82 HBsAg-positive patients. Results: Among all enrolled patients, 14.1% were HBsAg-positive. The HBV reactivation rate was 9.8% among evaluable HBsAg-positive patients, and reactivation was not independently linked to survival. After adjustment, baseline HBsAg positivity showed a borderline trend toward poorer OS (HR = 1.42, 95% CI, 0.99–2.04, p = 0.054) without significant PFS association (HR = 1.14, 95% CI, 0.80–1.62, p = 0.481). Liver metastasis independently predicted worse OS in HBsAg-positive patients (HR = 3.84, 95% CI, 1.65–8.94, p = 0.002). Conclusions: HBV reactivation was uncommon but warrants close monitoring during EGFR-TKI therapy. Baseline HBsAg positivity demonstrated only a non-significant trend toward inferior OS without affecting PFS. Routine HBsAg screening at diagnosis may facilitate risk stratification, and HBsAg-positive patients with liver metastasis require intensified surveillance.
SN - 2072-6694
ER -